Tag: Jayson Dallas

Nestlé to fully own Aimmune Therapeutics through $2bn deal

pharmanewsdaily- September 1, 2020

Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in ... Read More

First patients being treated with Aimmune’s PALFORZIA peanut allergy drug

pharmanewsdaily- March 17, 2020

Aimmune Therapeutics said that the first patients in the US are being treated with the recently FDA approved peanut allergy drug PALFORZIA . The California-based ... Read More

Nestlé increases stake in Aimmune Therapeutics after Palforzia FDA approval

pharmanewsdaily- February 9, 2020

Aimmune Therapeutics, which has recently bagged approval from the US Food and Drug Administration (FDA) for its peanut allergy drug PALFORZIA (formerly AR101), has secured ... Read More

Aimmune Therapeutics bags Palforzia FDA approval for peanut allergy

pharmanewsdaily- February 3, 2020

Palforzia FDA approval : Aimmune Therapeutics has been granted approval from the US Food and Drug Administration (FDA) for Palforzia for the treatment of peanut ... Read More